Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Viridian Therapeutics, Inc.
This is a randomized (meaning participants will be assigned to study arms by chance), double-masked (meaning study doctor and participant will not know which study arm participant is assigned to), placebo-controlled study that will include participants with chronic TED. The key objectives of this study are to determine if veligrotug (VRDN-001) is efficacious, safe, and tolerable when administered as 5 IV infusions given every 3 weeks for a total of 12 weeks in participants with chronic TED.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have moderate to severe chronic TED with documented evidence of ocular symptoms or signs that began greater than 15 months prior to screening
Must have had a clinical diagnosis of TED, with any CAS (0-7)
Must agree to use highly effective contraception as specified in the protocol
Female TED participants must have a negative serum pregnancy test at screening
You may not be if
Must not have received prior treatment with another anti-IGF-1R therapy
Must not have received systemic corticosteroids for any condition, including TED, or selenium within 2 weeks prior to first dose
Must not have received other immunosuppressive drugs or another investigational agent for any condition, including TED, or any other therapy for TED, within 8 weeks prior to first dose
Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose
Must not have a pre-existing ophthalmic condition in the study eye that in the opinion of the study doctor would confound interpretation of the study results
Must not have had previous orbital irradiation or decompression surgery for TED to the study eye's orbit
Must not have inflammatory bowel disease
Must not have abnormal baseline audiometry Pure Tone Average (PTA) assessment or history of significant (as determined by the Investigator) ear pathology, relevant ear surgery or hearing loss.
Female TED participants must not be pregnant or lactating